In contrast, a recent report demonstrated that genetic deletion Il-1β failed to improve fatigue symptoms in several different rodent models of cancer, suggesting that, while IL-1β signaling may initiate or drive some cachexia symptoms, it is unlikely to be an all-encompassing therapeutic target [53]. The gene discussed is IL1B; the disease is cancer.